GC Biopharma said Monday that its flu vaccine, GCFLU, has won the full bid for Thailand's national vaccination program from the Government Pharmaceutical Organization (GPO) for the second year in a row.

With this latest bid, GC Biopharma has secured a cumulative total of over 10 million doses, winning all 4.07 million doses in this round. GCFLU is exported to 63 countries worldwide and has established itself as a leading domestic flu vaccine, expanding both its market reach and volume annually. The company has been active in the Thai flu vaccine market since 2014.

According to GC Biopharma, active administrative support from the Ministry of Food and Drug Safety  (MFDS) since last year has facilitated overseas export contracts, including expedited export approvals. 

“GCFLU, recognized for its product reliability in international procurement markets, is also achieving positive results in public markets of individual countries,” said Lee Woo-jin, head of GC Biopharma’s global business division. “We will continue to solidify the position of excellent domestic vaccines in overseas markets.”

A GC Biopharma official added that the company is the largest seasonal flu vaccine supplier for international organizations under the WHO, having produced over 300 million doses last year.